MEDIUS HOLDINGS Co.,Ltd. Q2 FY2025 earnings call

• Company Overview & Positioning:

  • メディアスホールディングス is the largest medical device wholesaler in Japan by wholesale sales volume, operating in a 372.4 billion yen (0.3724 trillion yen) domestic end-market with ~1,000 competing distributors, only 7 of which have annual sales over 10 billion yen.
  • The group comprises 14 operating companies, covering general medical device distribution, plus specialized segments: device maintenance, portable medical device rental (infusion pumps, syringe pumps), hospital IT solutions, and dedicated nursing care equipment distribution. It carries over 1 million product SKUs ranging from basic consumables (masks, gloves) to advanced devices (endoscopes, MRIs, da Vinci surgical robots).
  • It sources products from all major global and domestic medical device manufacturers, including Medtronic, Johnson & Johnson, Siemens Healthineers, FUJIFILM Medical, Olympus, Terumo, and Canon.

• Total Solution Service Offerings:

  • Meccul: Medical device price analysis system using a proprietary database of pricing data from 2,000 hospitals to support procurement decision-making.
  • SURGELANE: Operating room management IT software that tracks average procedure time and costs to improve OR efficiency, a historically under-optimized area for most hospitals.
  • SPD: Consignment inventory system that places stocked medical materials at hospital sites, billing only for used products. Eliminates hospital inventory management work and reduces expired material waste (previously ~5% of inventory for most facilities). A simplified version called STORE is available for hospitals with fewer than 300 beds.
  • ASOURCE DATABASE: Central catalog database for the group's nearly 1 million SKUs of medical materials.

• Strategic Priorities (2025–2027 Mid-Term Plan):

  • Shifted strategic focus from market share growth to profit growth, in response to rising inflation and increasing labor costs.
  • Leverage existing expertise and information networks to expand high-margin solution service sales.
  • Strengthen sales focus on acute care hospitals (the largest consumer of medical devices) as the Japanese hospital market continues to split between acute care and chronic care facilities.
  • Prioritize product expansion in the fast-growing minimally invasive surgery device space.
  • Expand private label product lines, building on supply chain experience gained during the COVID-19 pandemic when direct sourcing helped maintain supply of critical products.
  • Build regional BCP (Business Continuity Planning) capabilities to ensure stable supply during natural disasters or pandemics.
  • Continue M&A as a core growth strategy, prioritizing horizontal M&A to build a nationwide comprehensive distribution footprint first, before pursuing vertical M&A targeting suppliers.
  • Strengthen group management via cross-organizational initiatives, personnel exchanges, shared IT and logistics infrastructure, centralized administrative operations, and improved post-M&A integration (PMI).

• Capital & Shareholder Strategy:

  • Current PBR trades around 1x, with a target to consistently hold PBR above 1x. ROE has declined recently due to continued capital investment, with a plan to improve ROE going forward.
  • Target a 30%+ payout ratio, with a 2025 June year projected dividend of 19 yen per share (down from 21 yen in the prior year).
  • Maintains a shareholder yield program with QUO cards or equivalent donations to Doctors Without Borders for qualifying holdings.

For the first half of the 2025 June fiscal year (interim results): Reported sales were 142.7 billion yen, 112.6% of the prior year period. Operating income was 0.751 billion yen, 110.3% of the prior year period. Ordinary income was 0.983 billion yen. Interim net income was 0.406 billion yen, 80.5% of the prior year period. By customer segment: 50% of revenue comes from public medical institutions (national, prefectural, and municipal hospitals), and 50% comes from private medical institutions including private university hospitals and private hospital groups. No separate financial performance figures are provided for the firm's other business lines (device maintenance, device rental, solution services, nursing care equipment).

• Full year 2025 June fiscal year guidance is maintained at: 280 billion yen in sales, 1.4 billion yen in operating income, 2.0 billion yen in ordinary income, and 1.28 billion yen in net income.
• The 2025–2027 mid-term plan maintains a target of 320 billion yen in sales and 2.42 billion yen in ordinary income for the 2027 June fiscal year, representing a 10% annual growth target for ordinary income.
• The company expects the domestic medical device market to grow at a 2%–3% annual rate through 2040, driven by an aging population that will keep demand for medical and long-term care rising, despite ongoing negative price revisions from biennial medical fee updates.

• Biennial medical fee revisions have resulted in 16 consecutive years of downward price adjustments for medical devices, squeezing industry margins and contributing to a "device lag" where new imported devices are slow to enter the Japanese market due to limited profit potential for manufacturers.
• Physician work style reform presents structural challenges to the entire Japanese healthcare system, and requires fundamental changes to care delivery models that create both risks and opportunities for the company.
• Long-term demographic decline after 2040 is expected to reduce overall patient volumes and put further pressure on medical institution profitability.
• The fragmented industry structure (1,000 competing distributors) remains inefficient for both manufacturers and hospitals, and will require further consolidation to improve industry profitability.

Q: Why have hundreds of small distributors with under 1 billion yen in annual sales survived in the market, and will consolidation accelerate going forward? / A: The industry grew rapidly after World War II with the rise of disposable medical products, which led local distributors to build long-term personal trust-based relationships with regional hospitals. Hospitals have preferred to keep these trusted relationships, leading to the current fragmented structure. Going forward, as hospitals face greater cost pressure and demand lower-priced, reliable supplies, and manufacturers want to sell through a smaller number of efficient distributors to reach the shrinking market, industry consolidation and oligopolization will accelerate.

Q: With the long-term expectation of population decline reducing demand, how does the company plan to navigate this future? / A: Even after 2040, demand for geriatric care will continue to grow even as youth patient volumes decline, but medical institutions will face greater profitability pressure and need to improve operational efficiency. The company will target growth by supporting medical institutions in high-demand areas including preventive care, digitalization, and ICT implementation.

Q: Is all future growth dependent on M&A, or is there organic growth potential in existing businesses? / A: There is significant room for organic share growth and profitability improvement in existing service areas. The company will prioritize profit improvement in existing operating regions, with continued gradual organic share growth, while M&A will be focused on gaining share in untapped geographic regions.

Q: How does physician work style reform impact the company, and how is the company positioned for this trend? / A: Work style reform is a net negative structural change for the industry, and fundamental changes to care delivery are required to maintain current service levels. The company's solution services aim to help move non-specialized work away from physicians and nurses to let them focus on high-skill clinical tasks, which the company believes will increase demand for its solution offerings.